ALK-positive NSCLC - Lorlatinib still effective after 5 Years

Anaplastic lymphoma kinase (ALK) inhibitors are the first-line standard for patients with ALK-positive non-small cell lung cancer (NSCLC). The third-generation brain-penetrating ALK tyrosine kinase inhibitor (TKI) lorlatinib was significantly more effective in the CROWN study than the older crizotinib in terms of progression-free survival (PFS) and confirmed this advantage after 3 years of follow-up - regardless of the presence of CNS metastases. In a recent post-hoc analysis, the efficacy and safety of lorlatinib were examined after 5 years of follow-up.